New York, Jan 26, 2026, 16:37 EST — After-hours
- Moderna shares ended down 1.5%, holding steady after hours
- The company scheduled its fourth-quarter results and corporate update for Feb. 13
- Biotech ETFs showed a mixed performance, while big pharma stocks moved unevenly
Moderna, Inc. shares closed Monday down 1.5% at $47.98. In after-hours trading, which follows the 4 p.m. close, the stock held steady around $47.99.
The vaccine maker announced Monday it will release its fourth-quarter 2025 results on Feb. 13, followed by a conference call and webcast at 8 a.m. ET. Executives are set to provide a corporate update during the session.
Investors are now eyeing that date as the next key checkpoint to assess how rapidly Moderna can stabilize both revenue and expenses while shifting focus beyond its COVID-19 portfolio.
Biotech stocks saw mixed action. The iShares Nasdaq Biotechnology ETF edged up roughly 0.3% late Monday, but the SPDR S&P Biotech ETF slipped a bit.
Moderna’s Feb. 13 call will probably zero in on the data rather than headlines: how demand is shaping up for its respiratory vaccines, the speed of its R&D spending, and any changes to timelines for major projects.
Shares diverged among peers. Merck, partnered with Moderna in oncology, slipped roughly 0.8%, while Pfizer climbed nearly 0.9%.
The stock has seen wild swings this January. It surged 15.8% on Jan. 21, climbed another 4.1% the following day, then dropped 6.1% on Jan. 23, and slid further on Monday.
Bulls face the risk that the next update could shift expectations unfavorably — weaker vaccine demand, rising costs, or slower clinical progress might drag shares down fast, especially following recent swings.
Next on the docket: Moderna reports earnings on Feb. 13, followed by a conference call at 8 a.m. ET. Investors are set to challenge management on 2026 goals and the outlook heading into 2027.
Related articles: NASDAQ:MRNA
